Chairman of the Board Hans Peter Bøhn , MD (Born 1955)
HPBHans Peter Bøhn is a Norwegian citizen with a medical degree.  He started his pharmaceutical industry career as medical adviser in Nycomed Imaging. Over the ensuing 12 years he gained broad experience from management positions in the pharmaceutical industry within drug safety, international marketing and operations and clinical research as well as gaining a post-graduate Diploma of Pharmaceutical  Medicine. After the years in the industry he joined Fondsfinans as a financial analyst covering the life science sector.  From 2012 he has been manager of the non-profit “Svanhild og Arne Musts Fond for Medisinsk Forskning” as well as serving as an independent adviser to among others the Research Council of Norway, the Norwegian Cancer Society, Innovation Norway, Oslo Cancer Cluster as well as a number of biotech start-up companies. He has been a Board member of PCI Biotech Holding ASA since 2015.

Board member Dr. Hilde Hermansen Steineger, PhD (Born 1966)
Dr. Steineger holds a PhD in Medical Biochemistry from the University of Oslo, Norway. She previously served as Strategic Innovation Management Nutrition & Health in BASF, and previously served as Head of Innovation Management of Pronova BioPharma AS/ BASF. Dr. Steineger has held positions as VP IR & Communications at Pronova BioPharma, as Senior Associate with Neomed Management, and as equity analyst at Kreditkassen (now part of Nordea Markets) based in Oslo and Copenhagen. She has also worked as an independent advisor focusing on start-ups in Life Science/Health Care. Dr. Steineger is a co-founder of NorthSea Therapeutics B.V. in which she currently holds the position as Chief Operating Officer. Dr. Steineger is currently a Board member at Strongbridge Biopharma plc and Nordic Nanovector ASA. She has been a Board member of PCI Biotech Holding ASA since May 2014.

Board member Dr. Christina Herder, PhD (Born 1961)
Dr. Herder currently holds the position as Executive Vice President at Medivir AB (listed at Nasdaq, Stockholm). Prior to that she was the CEO of Modus Therapeutics AB, a Swedish drug development company. She has over 25 years of experience from the life science industry, both from the areas of drug development as well as business development. Previous positions include Sobi, where she built up the portfolio management function and worked with Corporate Development. She holds a PhD from Royal Institute of Technology in Stockholm, Sweden, and an MBA from Stockholm University. Dr. Herder also serve as Board member of Idogen AB (listed at AktieTorget). She has been a Board member of PCI Biotech Holding ASA since 2015.

Board member Lars Viksmoen, MD (Born 1949)
Dr. Viksmoen is Norwegian citizen and MD from University of Oslo, Norway.  After 10 years as surgeon he started his professional life in the pharma industry at the Norwegian subsidiary of Merck & Co. Inc. in 1990. During the last 25 years he has gained a broad international experience through several international management and executive roles within the pharma, biotech as well as medtech industry. His main responsibilities and capabilities have been within commercialization of innovation, i.e. managing and leading commercial focused business unites and organisations. In addition, he has over the last close to 10 years broad experience leading listed companies. His last position has been as President and CEO of GN ReSound AS, Denmark, the fourth largest hearing-aid manufacture worldwide, listed in Denmark. He became a Board member of PCI Biotech Holding ASA in May 2016.

Board Member Professor Andrew Hughes, MD, PhD (born 1964)
Professor Hughes holds an MD from Cambridge, UK, and a PhD degree in behavioural neuroendocrinology. After practicing general clinical medicine in Manchester’s teaching hospitals, he joined Zeneca in 1994.  He had roles of growing managerial responsibility in AstraZeneca, including Worldwide Director of Discovery Medicine; Oncology and Infection, Worldwide Clinical Head of Early Phase Oncology, and most recently Global VP of Early Clinical Development. He has been clinical investigator on over 200 clinical trials and leading over 50 research and early clinical development programmes of novel candidate drugs. Currently Professor Hughes holds a position as Strategy Director of the experimental cancer medicine at Manchester Cancer Research Centre, UK. In 2006, he was appointed to a chair of Translational medicine at the University of Manchester, UK. He became a Board member of PCI Biotech Holding ASA in May 2018.